BR112022008208A2 - Compostos de d-anfetamina, composições e processos para produzir e usar os mesmos - Google Patents

Compostos de d-anfetamina, composições e processos para produzir e usar os mesmos

Info

Publication number
BR112022008208A2
BR112022008208A2 BR112022008208A BR112022008208A BR112022008208A2 BR 112022008208 A2 BR112022008208 A2 BR 112022008208A2 BR 112022008208 A BR112022008208 A BR 112022008208A BR 112022008208 A BR112022008208 A BR 112022008208A BR 112022008208 A2 BR112022008208 A2 BR 112022008208A2
Authority
BR
Brazil
Prior art keywords
compositions
producing
processes
amphetamine compounds
amphetamine
Prior art date
Application number
BR112022008208A
Other languages
English (en)
Portuguese (pt)
Inventor
Guenther Sven
Chi Guochen
Mickle Travis
Original Assignee
Kempharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kempharm Inc filed Critical Kempharm Inc
Publication of BR112022008208A2 publication Critical patent/BR112022008208A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
BR112022008208A 2018-10-29 2020-02-21 Compostos de d-anfetamina, composições e processos para produzir e usar os mesmos BR112022008208A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862752324P 2018-10-29 2018-10-29
US201962800494P 2019-02-02 2019-02-02
US16/667,807 US11174229B2 (en) 2018-10-29 2019-10-29 D-amphetamine compounds, compositions, and processes for making and using the same
PCT/US2020/019146 WO2021086427A1 (en) 2018-10-29 2020-02-21 D-amphetamine compounds, compositions, and processes for making and using the same

Publications (1)

Publication Number Publication Date
BR112022008208A2 true BR112022008208A2 (pt) 2022-07-12

Family

ID=70328134

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022008208A BR112022008208A2 (pt) 2018-10-29 2020-02-21 Compostos de d-anfetamina, composições e processos para produzir e usar os mesmos
BR112022008216A BR112022008216A2 (pt) 2018-10-29 2020-02-21 Compostos de d-anfetamina, composições e processos de fabricação e uso dos mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022008216A BR112022008216A2 (pt) 2018-10-29 2020-02-21 Compostos de d-anfetamina, composições e processos de fabricação e uso dos mesmos

Country Status (13)

Country Link
US (4) US11174229B2 (https=)
EP (2) EP4051268A4 (https=)
JP (5) JP7653429B2 (https=)
KR (3) KR20220088727A (https=)
CN (2) CN114746091A (https=)
AU (2) AU2020372736A1 (https=)
BR (2) BR112022008208A2 (https=)
CA (2) CA3158405A1 (https=)
IL (2) IL292496A (https=)
MX (2) MX2022005013A (https=)
PH (2) PH12022551047A1 (https=)
WO (2) WO2021086426A1 (https=)
ZA (2) ZA202204678B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174229B2 (en) * 2018-10-29 2021-11-16 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same
CN120131637A (zh) * 2025-05-08 2025-06-13 中国人民解放军海军军医大学 左乙拉西坦在制备抗疲劳的药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02504509A (ja) * 1987-08-07 1990-12-20 ジ・アップジョン・カンパニー 非ペプチド結合を有するレニン抑制ペプチド
DE4234012A1 (de) * 1992-10-09 1994-04-14 Basf Ag Neue Anilinderivate und diese enthaltende Pflanzenschutzmittel
AU1494702A (en) * 2000-11-21 2002-06-03 Leo Pharma As Cyanoguanidine prodrugs
SI1644019T2 (en) 2003-05-29 2018-04-30 Shire Llc Abuse resistant amphetamine compounds
US8163701B2 (en) 2005-08-19 2012-04-24 Signature Therapeutics, Inc. Prodrugs of active agents
CA2763172A1 (en) 2009-05-26 2010-12-02 David Hackett Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
CA3123900A1 (en) * 2011-07-28 2013-01-31 Kempharm Inc. Methylphenidate-prodrugs, processes of making and using the same
BR102012004888A2 (pt) 2012-03-05 2013-10-22 Phartrials Pesquisas Farmaceuticas Ltda Associação de um derivado de sulfamato monossubstituído do monossacarídeo natural d-frutose (topiramato) com um anti-depressivo da classe das fenilcetonas (bupropiona) para tratamento de obesidade e das síndromes plurimetabólicas
US20140073589A1 (en) * 2012-06-27 2014-03-13 Shire Ag Amphetamine Prodrugs
AU2013326850B2 (en) * 2012-10-04 2017-09-21 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
JP6621329B2 (ja) * 2012-10-05 2019-12-18 スファエラ ファーマ ピーティーイー リミテッド 新規化合物、それらの合成及びそれらの使用
ITUA20161706A1 (it) * 2016-03-15 2017-09-15 Cyanagen S R L Nuovi coloranti cumarinici e relativi coniugati
HUE067004T2 (hu) * 2016-12-11 2024-10-28 Zevra Therapeutics Inc Metilfenidát prodrogokat tartalmazó készítmények, eljárások azok elõállítására és felhasználására
US20200114014A1 (en) 2017-04-11 2020-04-16 John K. Thottathil Novel Alpha-Hydroxy Carboxylic Acid and Derivatives and Other GRAS-Based Amide and Imide Prodrugs of Amphetamine Compounds and Uses Thereof
US20200109117A1 (en) * 2018-10-02 2020-04-09 ACCESS Association Modified Therapeutic Agent Analogs of Mefenamic Acid
US11174229B2 (en) * 2018-10-29 2021-11-16 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same

Also Published As

Publication number Publication date
US12091386B2 (en) 2024-09-17
US11174229B2 (en) 2021-11-16
NZ787388A (en) 2025-05-02
JP7653429B2 (ja) 2025-03-28
JP2023501968A (ja) 2023-01-20
JP2024091930A (ja) 2024-07-05
US20240199551A1 (en) 2024-06-20
MX2022005013A (es) 2022-08-10
CA3158404A1 (en) 2021-05-06
AU2020376735A1 (en) 2022-05-12
BR112022008216A2 (pt) 2022-07-12
KR20260025885A (ko) 2026-02-24
CN114746091A (zh) 2022-07-12
US20200131130A1 (en) 2020-04-30
EP4051269A4 (en) 2023-12-27
JP7830540B2 (ja) 2026-03-16
JP2025163212A (ja) 2025-10-28
EP4051268A1 (en) 2022-09-07
EP4051269A1 (en) 2022-09-07
CN114746092A (zh) 2022-07-12
NZ787387A (en) 2025-05-02
US20220064116A1 (en) 2022-03-03
CA3158405A1 (en) 2021-05-06
IL292496A (en) 2022-06-01
JP2023501967A (ja) 2023-01-20
PH12022550996A1 (en) 2023-10-02
PH12022551047A1 (en) 2023-05-03
ZA202204678B (en) 2023-01-25
ZA202204747B (en) 2023-05-31
US20200129497A1 (en) 2020-04-30
WO2021086426A1 (en) 2021-05-06
JP2025023120A (ja) 2025-02-14
MX2022005012A (es) 2022-08-08
US11136295B2 (en) 2021-10-05
IL292497A (en) 2022-06-01
AU2020372736A1 (en) 2022-05-12
EP4051268A4 (en) 2024-01-17
KR20220091508A (ko) 2022-06-30
JP7653428B2 (ja) 2025-03-28
KR20220088727A (ko) 2022-06-28
WO2021086427A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
CO2021005987A2 (es) Compuestos de anillo fusionado
CO2021003036A2 (es) Compuestos de anillo fusionado
CY1122994T1 (el) Μεθοδος καθαρισμου κανναβινοειλων, συνθεσεων και kit αυτων
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
BR112019005595A2 (pt) compostos e métodos para modulação de ido e tdo, e indicações para os mesmos
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112021022758A2 (pt) Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112018007381A2 (pt) compostos úteis como imunomoduladores
BR112018004620A2 (pt) moduladores da expressão de kras
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
BR112018005194A2 (pt) processo de composto antifúngico
BR112017013661A8 (pt) Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica
BR112017004925A2 (pt) composição e método
BR112023023578A2 (pt) Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
BR112017008794A2 (pt) inibidores de di-heteroaril histona desacetilase e seu uso em terapia
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
BR112022008208A2 (pt) Compostos de d-anfetamina, composições e processos para produzir e usar os mesmos
BR112017026319A2 (pt) mistura de iniciadores, composição, sua utilização, processo de preparação de um polímero poliol e polímero poliol obtido pelo processo
BR112021026061A2 (pt) Método para o tratamento de uma composição que compreende vanilina natural
BR112016003511A8 (pt) composição farmacêutica que contém derivado de hidantoína
BR112019001824A2 (pt) compostos de tiazol-piridina substituídos como inibidores de malt1
BR112018073300A2 (pt) métodos para tratamento de doenças associadas com as células ilc3

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ZEVRA THERAPEUTICS, INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]